RNAZ Stock — TransCode Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.65

Market cap

$27.9M

Cash

$8.4M

Enterprise value

$19.5M

Balance sheet

Cash	$8.4M
Debt	$0.0M
Net cash	$8.4M
Enterprise value	$19.5M
Basic shares	1.0M shares
Fully diluted shares	16.9M shares
Fully diluted market cap	$28.0M
Cash per share	$8.38

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading RNAZ daily closes…

Loading price history…

Pipeline assets

TTX-MC138

Phase 2 · Active Modality: oligonucleotide conjugated to iron oxide nanoparticle

Target miR-10b

Indications

Metastatic cancer (Phase 1a, patients continuing on trial) (Phase 1)
Colorectal cancer at high risk of recurrence after curative-intent therapy (Phase 2a) (Phase 2)

Catalysts

— Q3 2026

Status note Lead candidate: oligonucleotide conjugated to an iron oxide nanoparticle, administered by infusion, designed to inhibit the ability of metastatic tumor cells to survive. Phase 1a trial (commenced Q3 2024) ongoing with patients continuing. Phase 2a trial in colorectal cancer patients at high risk of recurrence initiated Q2 2026; initial enrollment expected Q3 2026.

Seviprotimut-L

Stage not disclosed · Active

Indications

Stage IIB and IIC melanoma micrometastases (potential combination with TTX-MC138) (Stage not disclosed)

Status note Additional pipeline cancer therapy candidate; company evaluating potential to augment its anti-cancer effects by combining with TTX-MC138 to address micrometastases in stage IIB/IIC melanoma. Phase not disclosed in the excerpts.

Adenovirus candidate program

Preclinical · Active Modality: genetically-engineered adenoviruses

Partnerships Licensed from Unleash Immuno Oncolytics, Inc.

Indications

Cancer (Preclinical)

Status note Pre-clinical candidate program involving genetically-engineered adenoviruses to harness the immune system to fight cancer, licensed from Unleash Immuno Oncolytics.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05868226	Phase 2	Recruiting	Collaborator	QuantumLeap Healthcare Collaborative	PFE	HER2-positive Breast Cancer; Metastatic Cancer; Metastatic Breast Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for QuantumLeap Healthcare Collaborative on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

RNAZ — TransCode Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Active clinical trials